Abstract:Purpose: Triple-negative breast cancer is characterized by fast progression with high possible for metastasis and poor survival. Dysfunction of microRNAs plays an important role in the initiation and progression of cancer. Our previous microRNA-seq data indicated the downregulation of miR-331-3p in triple-negative breast cancer tissues compared with that of the noncancer tissues. However, the function of miR-331-3p in triple-negative breast cancer remains largely unknown. Herein, the involvement of miR-331-3p in triple-negative breast cancer was investigated and the therapeutic potential of miR-331-3p was also explored. Methods: Real-time quantitative polymerase chain reaction was performed to detect the expression of miR-331-3p in triple-negative breast cancer tissues and cell lines. The cell proliferation was determined by the cell counting kit-8 assay. Apoptosis of triple-negative breast cancer cells was examined by annexin V/propidium iodide staining. miRDB database was used to predict the potential targets of miR-331-3p. Western blot was performed to examine the expression of the target protein. Results: miR-331-3p was significantly downregulated in triple-negative breast cancer tissues and cell line. Lower miR-331-3p expression was significantly correlated with the tumor size, TNM stage, and lymph node metastasis of patients with triple-negative breast cancer. Functional experiments showed that the overexpression of miR-331-3p inhibited the proliferation and increased apoptosis of triple-negative breast cancer cells. Neuropilin-2 was identified as a target of miR-331-3p, which harbored binding site of miR-331-3p in its 3 '-untranslated region. Overexpression of miR-331-3p decreased the messenger RNA and protein levels of neuropilin-2 in triple-negative breast cancer cells. Restoration of neuropilin-2 partially reversed the inhibitory effects of miR-331-3p on the proliferation of triple-negative breast cancer cells. Conclusions: Our results demonstrated the novel function of miR-331-3p/neuropilin-2 signaling in regulating the malignant behaviors of triple-negative breast cancer cells, which suggested miR-331-3p as a potential target for the treatment of triple-negative breast cancer.

MiR-27a-3p Targeting GSK3β Promotes Triple-Negative Breast Cancer Proliferation and Migration Through Wnt/β-Catenin Pathway

Mir-27a Regulates Wnt/Beta-Catenin Signaling Through Targeting Sfrp1 in Glioma

MiR-27a Facilitates Breast Cancer Progression Via GSK-3β

MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

Regulation of Cancerous Progression and Epithelial-Mesenchymal Transition by Mir-34C-3p Via Modulation of MAP3K2 Signaling in Triple-Negative Breast Cancer Cells.

Bioinformatics Identification of Dysregulated Micrornas in Triple Negative Breast Cancer Based on Microrna Expression Profiling.

MicroRNA‑126‑3p inhibits the proliferation, migration, invasion, and angiogenesis of triple‑negative breast cancer cells by targeting RGS3.

The Micrornas Mir-200B-3p and Mir-429-5p Target the LIMK1/CFL1 Pathway to Inhibit Growth and Motility of Breast Cancer Cells

Mir-27A-3p Regulates Proliferation and Apoptosis of Colon Cancer Cells by Potentially Targeting BTG1

Mir-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2

Companion Diagnostics and Cancer Biomarkers miR-185 Suppresses Tumor Proliferation by Directly Targeting E 2 F 6 and DNMT 1 and Indirectly Upregulating BRCA 1 in Triple-Negative Breast Cancer

miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells

miR-301b-3p Regulates Breast Cancer Cell Proliferation, Migration, and Invasion by Targeting NR3C2

MicroRNA-27a-3p Reverses Adriamycin Resistance by Targeting BTG2 and Activating PI3K/Akt Pathway in Breast Cancer Cells

MicroRNA-3613-3p Functions As a Tumor Suppressor and Represents a Novel Therapeutic Target in Breast Cancer.

miR-221/222 activate the Wnt/β-catenin signaling to promote triple negative breast cancer.

miRNA-200c-3p deficiency promotes epithelial-mesenchymal transition in triple-negative breast cancer by activating CRKL expression

miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling

Mir-27a-3p Targeting Rxr Alpha Promotes Colorectal Cancer Progression By Activating Wnt/Beta-Catenin Pathway

Tumor-suppressor miRNA-27b-5p regulates the growth and metastatic behaviors of ovarian carcinoma cells by targeting CXCL1